Eckert & Ziegler Q2 / 2017: Income Surges Following Sale of Cyclotron Unit. Net Liquidity Exceeds EUR 40 Million. Group Almost Debt-free.

Berlin, 2 August 2017. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a Berlin-based company specializing in isotope technology for medical, scientific and industrial applications, nearly doubled its profit per share by 0.91 EUR to 1.83 EUR in the first half year compared with the prior year's period. The improved financial performance is primarily the result of increased sales with profitable products and an extraordinary income from the sale of the Cyclotron unit in May 2017. Without discontinued operations and thereby according to regulations required under IFRS 5 profit per year increased by 0.34 EUR or 23% to 1.23 EUR compared with the prior year's period.

Taking into account the adjustments required under IFRS5 the Group recorded total sales of EUR 64.8 million EUR in the first half of 2017 (+6%). Including discontinued operations the Group recorded total sales of EUR 71.0 million in the first half of 2017, compared with EUR 70.1 million in the prior year's period. Organic, real sales growth - in other words, sales adjusted for currency effects and excluding the acquisitions and disposals made in 2016 and 2017 - came to EUR 0.8 million.

The Radiopharma segment was the growth driver. If the discontinued Cyclotron unit is excluded, year-on-year growth was EUR 3.2 million or 31 %. In the USA in particular, the company further increased its already strong sales. Sales in the Radiation Therapy segment rose by EUR 0.2 million or 2 % to EUR 12.3 million. The Isotope Products segment continued to increase, growing EUR 0.5 million or 1 % to EUR 40.6 million.

Cash flow increased faster than earnings, causing net liquidity - in other words, cash and cash equivalents less total liabilities to banks - to rise by EUR 12 million to EUR 40 million. The Group is now almost debt-free.

As a result of the extraordinary income from the sale of the Cyclotron unit, earnings of around EUR 2.80 per share are forecast for 2017, EUR 0.60 of which is due to extraordinary effects and discontinued operations. Sales of just under EUR 150 million are expected.

The complete financial statements can be viewed here:
http://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz217e.pdf

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with approximately 760 employees, is one the world's largest providers of isotope technology for radiation therapy and nuclear medicine.
Contributing to saving lives.

For further information or questions, please contact:
Eckert & Ziegler AG
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com